Zoetis shares continue to struggle, down over 50% in the past year, as the company grapples with safety perception headwinds for its key Librela product and delayed product pipeline execution.
Zoetis shares experienced a significant decline during the second quarter of 2026 after the company issued a downward revision to its near-term earnings guidance. The performance was negatively impacted by persistent safety perception concerns surrounding its canine arthritis drug, Librela, alongside management's disclosure that the rollout of next-generation product launches will be delayed until the following year.
The decline was primarily driven by a downward revision to near-term earnings guidance and headwinds related to Librela safety concerns.
Management indicated that the ramp-up of next-generation product launches has been delayed and will extend into the following year.
Zoetis Inc. shares faced significant pressure in Q2 2026, dragging on the Impax US Sustainable Economy Fund's performance. The animal health company lowered its near-term earnings guidance, citing persistent safety concerns surrounding its Librela canine arthritis treatment and delays in the rollout of next-generation product launches.
The stock declined due to a downward revision in earnings guidance, driven by safety concerns regarding the Librela arthritis drug and delays in new product launches.